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Agreement of Direct Antifungal Susceptibility Testing from Positive
Blood Culture Bottles with the Conventional Method for Candida
Species
Kauser Jabeen,a Haresh Kumar,a Joveria Farooqi,a Raunaq Mehboob,a Mary E. Brandt,b Aﬁa Zafara
Section of Microbiology, Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistana; Mycotic Diseases Branch, Centers for Disease Control and
Prevention, Atlanta, Georgia, USAb
Early availability of antifungal susceptibilities can ensure timely institution of targeted therapy in candidemia, which can im-
prove patient outcomes. This study prospectively determines the agreement between the results of direct testing of antifungal
susceptibilities from blood culture bottles by disk diffusion and Etest and the results of standardized susceptibility testing meth-
ods; direct testing would allow susceptibility results to be available 1 to 2 days earlier. A total of 104 blood cultures with different
Candida species (28% C. albicans, 27% C. parapsilosis, 26% C. tropicalis, etc.) were evaluated between January 2012 and May
2013 for agreement of fluconazole, voriconazole, and amphotericin B susceptibility results by disk diffusion. Agreement inMICs
obtained by Etest was determined for fluconazole (21 isolates), voriconazole (28 isolates), amphotericin (29 isolates), and caspo-
fungin (29 isolates). The kappa scores for categorical agreement were highest for fluconazole by disk diffusion (0.902, standard
error [SE] 0.076) and Etest (1.00, SE 0.218) and for amphotericin B by disk diffusion (1.00, SE 0.098). The Pearson corre-
lation (r) of zone diameters was strongest for fluconazole (0.69) and amphotericin (0.70) andmoderate for voriconazole (0.60),
and the Pearson correlation of MICs was strongest for fluconazole (0.94) and caspofungin (0.88). However, the moderate corre-
lation of amphotericin MICs with zone diameters (0.42) precludes the use of amphotericin B disk diffusion for susceptibility
testing. There were no very major errors; however, there were 1 (1%)major and 5 (4.8%) minor errors with disk diffusion and 4
(13.3%) minor errors with Etest. Thus, antifungal disk diffusion directly from blood culture bottles is a rapid and easy method
for fluconazole and voriconazole susceptibility testing for timely tailoring of candidemia therapy.
Invasive fungal infections caused by members of the genus Can-dida are important causes of morbidity and mortality in immu-
nocompromised and hospitalized patients (1, 2). In hospitalized
patients, Candida species are the fourth most common cause of
bloodstream infections, with around 38% mortality (3, 4).
Globally, Candida albicans tends to be the most frequently (50
to 70%) reported species. In contrast, data from Pakistan report
non-albicans Candida species, mainly C. tropicalis, as the most
predominant species (5). With the emergence of non-albicans
Candida species in many settings, resistance to fluconazole is a
serious concern, as highlighted by recent surveillance data (6–8).
Increased mortality has been reported for candidemia patients
with delays in the initiation of appropriate antifungal therapy (9).
Patients receiving antifungal treatment more than 12 h after hav-
ing a positive blood culture sample drawn had a higher (33.1%)
risk of hospital mortality than patients begun on antifungal treat-
mentwithin 12 h (11.1%) (10).Hence, early and appropriate ther-
apy is essential to prevent severe complications and eventualmor-
tality.
The conventional method for determining fungal susceptibil-
ity requires subculturing of blood from bottles showing growth of
yeasts on solid agar and incubation of those plates for 24 to 48 h to
get growth of Candida species. Colonies are then used to prepare
inocula for susceptibility testing, and final reporting takes another
24 h (11). This delay could lead to serious consequences if the
species isolated is resistant to the empirical drug used for therapy.
Therefore, in clinical practice, a prompt and cost-effectivemethod
is needed to perform antifungal susceptibility testing.
Direct susceptibility testing from positive bottles has been
studied for bacterial pathogens and is now being used as standard
practice in clinical microbiology laboratories (12). This approach
has reduced the time from positivity of blood culture to prelimi-
nary reporting of susceptibility results. This practice has also been
evaluated for yeasts using Etest, which showed a 98% agreement
rate between direct susceptibility testing and the conventional
method (13, 14). A few other studies have evaluated direct suscep-
tibility testing using Vitek antifungal cards, Sensititre YeastOne,
and flow cytometry and have had various results (15–17). All of
these techniques are expensive and may not be practical in all
clinical laboratories.
The disk diffusion method is easy to perform in a clinical lab-
oratory, the materials required are more cost-effective than the
Etest, and clinical categorical interpretations of zone diameters of
fluconazole and voriconazole are available for common Candida
species (18). Thus, in this study, we evaluated direct disk diffusion
testing as an alternative to the conventional method to detect an-
tifungal susceptibilities. Direct determination of MICs with Etest
was also performed on a limited number of isolates.
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MATERIALS AND METHODS
Study background. This prospective study was conducted in the clinical
laboratory of the Aga Khan University Hospital (AKUH), Karachi, Paki-
stan, from January 2012 toMay 2013. The laboratory has a national spec-
imen collection network with more than 200 collection points in major
cities and towns across the country.
Specimens. A total of 104 blood culture specimens submitted to the
laboratory and smear positive for yeasts were included in this study.When
the incubated BacTec 9420 aerobic and/or anaerobic blood culture bottles
signaled positive, an aliquot was examined under themicroscope for bud-
ding yeast cells. Blood cultures positive for yeast mixed with bacteria were
excluded (data not recorded) from the study.
Organism identification. During the study period, Candida species
were identified using the standard protocol, as follows: germ tube produc-
tion, colony morphology on BiGGY agar (Becton Dickinson), urease test
(Oxoid), cycloheximide sensitivity test (Becton Dickinson), and presence
of pseudohyphae on cornmeal agar with Tween 80. Isolated colonies were
also evaluated for sugar assimilation on the biochemical test panel API
20C AUX (bioMérieux).
Direct antifungal susceptibility testing.The procedure for direct sus-
ceptibility testing frompositive blood cultureswas optimized as published
previously (19). The concentration of Candida species in a positive blood
culture bottle was not determined in this study, as a previous study has
shown that Candida cell counts in positive blood culture bottles were in
the range of 105 to 108 CFU/ml, with 87% of bottles having cell counts of
106 to 107 CFU/ml (exactly the count in 0.5 McFarland standards) (13).
One hundred-microliter amounts of uncentrifuged broth from smear-
positive blood culture bottles were used to make lawns on Mueller-Hin-
ton agar supplemented with 2% dextrose and 0.5 g/ml methylene blue
dye (MHA-MB). Neo-Sensitab (Rosco) disks with 25 g fluconazole, 25
g voriconazole, or 10 g amphotericin B were placed on the plates, and
the plates were incubated for 20 to 24 h at 35 2°C. CLSI disk diffusion
breakpoints using Rosco tablets have not been established and this prod-
uct is notwidely available; however, similar breakpoints have beenused by
other institutions using Rosco tablets (20). After 20 to 24 h, the zones of
inhibition around each disk were measured using a millimeter scale and
interpreted according to the manufacturer’s recommendations (20). For
voriconazole, for all species, the susceptible (S) inhibition zone diameter
was 17 mm, the susceptible–dose-dependent (S-DD) inhibition zone
diameter was 14 to 16mm, and the resistant (R) inhibition zone diameter
was13mm. For fluconazole,19mmwas interpreted as S, 15 to 18mm
as S-DD, and 14 mm as R for C. albicans, Candida parapsilosis, and C.
tropicalis and 15 mm was interpreted as S-DD and 14 mm as R for
Candida glabrata (18). For amphotericin B, a15-mm zone of complete
inhibitionwas interpreted as S, 10 to 14mmas intermediate susceptibility,
and 10 mm as R according to the manufacturer’s recommendations
(Neo-Sensitabs; Rosco), although there are no established interpretive
criteria for amphotericin B (20).
MIC determinations using Etest (AB Biodisk, Solna, Sweden) for flu-
conazole, voriconazole, amphotericin B, and caspofungin were per-
formed using RPMI agar as recommended by the manufacturer and read
at 24 h as recommended by CLSIM27-A3 (21). Susceptibility cutoffs were
determined using CLSI M27-S4 criteria (22). Although clinical break-
points or epidemiological cutoff values (ECVs) for amphotericin have not
been verified forMICs obtained by Etest, data suggest that brothmicrodi-
lution cutoffs may be used (23). Hence, for amphotericin B, an ECV of 2
g/mlwas used (24), and for thoseCandida species forwhichCLSI cutoffs
were not available, ECVs were used according to the recommendations of
Pfaller et al. (25).
Conventional antifungal susceptibility disk diffusion. The conven-
tional disk diffusion method was used as the gold standard for compari-
son (18). A lawn was made on MHA-MB using a suspension of Candida
species equal to 0.5 McFarland turbidity standard. Neo-Sensitab flucona-
zole (25g), voriconazole (25g), and amphotericin B (10g) diskswere
placed on the agar surface, and plates were incubated for 20 to 24 h at 35
2°C. After 20 to 24 h of incubation, the zones of inhibition around each
disk were measured and interpreted similarly to the direct testingmethod
described above. For fluconazole and voriconazole, the zone of inhibition
showing from 50 to 80% drop in growth was measured, while for ampho-
tericin B, the zone diameter from the point showing complete inhibition
of growth was measured. Etests against fluconazole, voriconazole, am-
photericin B, and caspofungin were performed (AB Biodisk, Solna, Swe-
den) using standard inocula from colonies on RPMI agar. For quality
control, Candida parapsilosis (ATCC 22019) and Candida krusei (ATCC
6258) were used with each new batch of medium prepared or new lot of
antifungal disks or Etests used.
Statistical analysis. Descriptive statistics were calculated using Mi-
crosoft Excel. Statistical analysis was performed with Stata 12 statistical
software. The frequencies of isolation of the different species and their
rates of resistance were calculated. Kappa scores were generated for cate-
gorical agreement, and the Pearson correlation test was applied to assess
whether the results of the direct disk diffusion and Etest methods of Can-
dida susceptibility testing correlated with the results from the standard
method. It was also applied to assess how well zone diameters correlated
withMICs for amphotericin B. The following standards were used for the
strength of agreement for the kappa coefficient: 0 to 0.0099, poor; 0.01 to
0.20, slight; 0.21 to 0.40, fair; 0.41 to 0.60,moderate; 0.61 to 0.80, substan-
tial; and 0.81 to 1, almost perfect.
A correlation coefficient of 0.8 was considered very strong correla-
tion, 0.6 to 0.79 strong, 0.4 to 0.59 moderate, 0.2 to 0.39 weak, and0.19
as veryweak. The Pearson chi-square test was used to evaluatewhether the
total number of errors in categorizing a strain as S, S-DD, or R was signif-
icantly associated with any species. For all statistical tests, a P value of
0.05 was considered significant.
RESULTS
One hundred six Candida species were isolated from 104 blood
culture bottles. Two cases had polymicrobial candidemia, with C.
albicans andC. krusei. Disk diffusion antifungal susceptibility test-
ing using the direct method and the conventional method was
performed on all 106 isolates, and Etest susceptibility testing was
performed on 21 isolates for fluconazole, 28 for voriconazole, and
29 for amphotericin and caspofungin. A description of the isolates
with their susceptibility patterns is shown in Table 1.
Comparison of the results of the conventional and the direct
susceptibility testingmethods by kappa score demonstrated excel-
TABLE 1 Description of Candida isolates included in the study
Organism(s)
No. of
isolates
% of
isolates
No. of isolates with indicated
susceptibilitya:
S-DD/I R
C. albicans 29 27.9 0 0
C. tropicalis 27 25.9 0 0
C. parapsilosis 28 26.9 1 to VRC 1 to FLC
C. glabrata 8 7.7 7 to FLC, 3 to CAS 1 to FLC
Non-albicans Candida 4 3.8 0 1 to FLC
C. lusitaniae 4 3.8 0 1 to FLC
C. pelliculosa 2 1.9 0 0
C. albicans C. kruseib 2 1.9 0 0
Total 104 100 9/104 4/104
a Isolates were categorized as S-DD and R to voriconazole and fluconazole when tested
according to standard protocol and susceptibility criteria as described in reference 18.
VRC, voriconazole; FLC, fluconazole; CAS, caspofungin; S-DD, susceptible-dose
dependent; I, intermediate susceptibility; R, resistant.
b These isolates were categorized according to the standard susceptibilities of the most
resistant of the two isolates (C. krusei in both cases).
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lent agreement for fluconazole using both disk diffusion and Etest
(Table 2) and for amphotericin using disk diffusion. Agreement
for voriconazole using disk diffusion was low because there was
only one nonsusceptible strain and the result was statistically in-
significant (P 0.56). The Etest results for voriconazole and am-
photericin B had 100% categorical agreement, but kappa scores
could not be generated because there was only one category, i.e.,
susceptible. Although the caspofungin MICs only differed by one
or two dilutions, they resulted in categorical disagreement and
only moderate agreement by kappa score.
The mean zone diameters, MICs, and correlation data are
shown in Table 3. The zone diameters from direct and standard
testing correlated well: the results for fluconazole and amphoter-
icin B correlated strongly, while the results for voriconazole cor-
related onlymoderatelywell. The Etest results were less consistent:
the results for fluconazole and caspofungin showed very strong
correlations and the results for voriconazole a moderate correla-
tion, while the amphotericin B MICs using Etest correlated very
weakly. The zone diameters of amphotericin B also correlated
moderately well with the amphotericin B MICs using Etest. All
correlation results were found to be statistically significant (P 
0.05) except for the Etest results for amphotericin B, which ap-
pears to be more inoculum dependent than other agents.
Analysis of major and minor errors in disk diffusion results
(Table 4) revealed 1 major error (for voriconazole against a C.
parapsilosis isolate) and 5 minor errors (for 2 C. tropicalis isolates,
2 C. parapsilosis isolates, and 1 C. albicans isolate) and no very
major errors. These errors were not found to be significantly as-
sociated with species. There were no major or very major errors
identified for the test method using Etest. However, four minor
errors were identified, including 2 cases of C. glabrata and 2 cases
of mixed C. krusei and C. albicans, showing that the probability of
error in direct caspofunginMICs for these specieswas greater than
by chance alone (P 0.001).
DISCUSSION
Wedetermined the agreement between the results of conventional
and direct antifungal susceptibility disk diffusion testing of flu-
conazole, voriconazole, and amphotericin B for Candida species
isolated from positive blood culture bottles. Additionally, the
agreement between conventional and direct susceptibility testing
using Etest was also assessed for fluconazole, voriconazole, am-
photericin B, and caspofungin.
Using disks, excellent agreement was observed for fluconazole
and amphotericin, confirmed by high kappa scores of 0.90 and
1.00, respectively. However, despite good reproducibility, the
zone diameters of amphotericin B correlated moderately with the
amphotericin B MICs, reconfirming that disk diffusion is not an
acceptable method for amphotericin B susceptibility testing using
either direct susceptibility or conventional disk diffusion testing.
TABLE 2 Agreement rates and kappa scores of the results of susceptibility testing performed directly from blood culture bottles and following
standard methodology
Antifungal Test modality No. of isolates tested Categorical agreement (%) Kappa score (SE) Kappa P value
Voriconazole Disk diffusion 104 97.12 0.0130 (0.0923)a 0.5559
Etest 28 100 —b —
Fluconazole Disk diffusion 104 97.12 0.9019 (0.0755) 0.0001
Etest 21 100 1.000 (0.2182) 0.0001
Amphotericin B Disk diffusion 104 100 1.000 (0.0981) 0.0001
Etest 29 100 —b —
Caspofungin Etest 29 86.21 0.4844 (0.1675) 0.0019
a The kappa score is negative because there was only one isolate in the nonsusceptible category and the expected agreement rate is higher than the detected agreement.
b —, the kappa statistic could not be generated due to too few categories (all isolates were susceptible with 100% agreement). The following standards for strength of agreement of
the kappa coefficient were used: 0 to 0.0099, poor; 0.01 to 0.20, slight; 0.21 to 0.40, fair; 0.41 to 0.60, moderate; 0.61 to 0.80, substantial; 0.81 to 1, almost perfect.
TABLE 3 Pearson correlation of zone diameters and Etest mean results and standard deviations
Antifungal Test modality
No. of isolates
tested
Mean value (SD) for disk diffusion
(mm) or Etest (g/ml) using:
Pearson correlation
(r) (strengtha) P valueDirect method Standard method
Voriconazole Disk diffusion 104 28.55 (5.45) 29.34 (5.64) 0.6040 (M) 0.0001
Etest 28 0.11 (0.12) 0.12 (0.16) 0.5808 (M) 0.0012
Fluconazole Disk diffusion 104 26.49(6.12) 26.94 (6.38) 0.6907 (S) 0.0001
Etest 21 2.76 (5.59) 3.66 (10.37) 0.9476 (VS) 0.0001
Amphotericin B Disk diffusion 104 21.78 (3.55) 21.72 (3.23) 0.7017(S) 0.0001
Etest 29 0.24 (0.26) 0.14 (0.13) 0.1637 (VW) 0.3875
Caspofungin Etest 29 0.32 (0.36) 0.24 (0.27) 0.8884 (VS) 0.0001
Amphotericin B Disk diffusion 29 23.37 (2.04) 0.14 (0.13) 0.4216 (M)b 0.0203
a VW, very weak; M, moderate; S, strong; VS, very strong.
b Zone diameter with MIC (both by standard method).
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The Pearson correlation test also showed a moderate to strong
correlation for azoles using standard and direct disk diffusion
testing.
Similar results (100% agreement) were obtained for direct sus-
ceptibility testing of fluconazole, voriconazole, and amphotericin
B using Etest. A slightly lower agreement (86%) with a moderate
kappa score of 0.4844was observed for caspofungin using Etest for
direct susceptibility testing, in spite of very strong correlation,
primarily due to minor errors (one dilution) at clinical break-
points for mixed cultures and for C. glabrata.
Only one study has previously evaluated the use of fluconazole
disks for direct susceptibility testing of Candida species; however,
that study used CHROMagar, which is not a recommended sus-
ceptibility testing medium (26). Another approach has been the
direct inoculation of Vitek antifungal cards for susceptibility test-
ing. However, the results of that study were suboptimal, with a
high number of errors (16). A recent study also evaluated direct
inoculation of Sensititre YeastOne from blood cultures for a lim-
ited number of cases (15). Although the results were good, this
approach is expensive and would not be practical in many re-
source-limited settings due to high shipping costs and shipment
delays. MHA with methylene blue and 2% glucose is a much
cheaper medium than RPMI broth for disc diffusion, and swab-
bing a lawn on a medium plate is easier and less technically de-
manding, resulting in less wastage than in broth-based suscepti-
bility methods.
As previously reported for direct susceptibility testing using
Etest (13), variations in the inoculum concentrations did not af-
fect the susceptibility results using disks, as all results were inter-
pretable after 24 h. This was also reflected by finding no significant
differences between the mean zone diameters and mean MICs by
conventional and direct method using either disks or Etest.
There were no very major errors in direct susceptibility testing
using either disks or Etest. Major errors using disks were noted
with only one strain ofC. parapsilosis, where the result for flucona-
zole was reported as resistant. No major errors were noted in di-
rect testing using Etest.
A high proportion of very major and major errors in direct
sensitivity testing using Etest has not been reported previously for
fluconazole, voriconazole, and caspofungin (14). Due to a high
rate of very major (3%) and major errors (23%) reported in am-
photericin B testing previously, direct susceptibility testing using
Etest for amphotericin B has not been recommended (14). We
noted no major errors in amphotericin B testing using disks and
no errors using Etest for direct susceptibility. However, as there
were no resistant isolates in our sample, the discriminatory ability
of this technique to detect resistance could not be assessed.
Amphotericin B deoxycholate is the first-line agent in Pakistan
for invasive candidiasis due to nonavailability of lipid prepara-
tions and echinocandins, and thus, amphotericin susceptibilities
are relevant in this setting. There has also been an upsurge in less
commonCandida species in our region in the last 5 years (27), and
therefore, it is important to document the susceptibility profiles of
naive and treated Candida strains. The clinical benefit usually lies
in whether the patient is currently on amphotericin therapy and
whether the patient would benefit from a higher dose than 0.7
g/ml.
Although a low percentage of C. krusei strains as agents of
candidemia from Pakistan has been reported previously, the fre-
quency is recent years has increased (27). Additionally, voricona-
zole treatment is also considered in patients at a high risk of con-
comitant invasive mold infection, for example, in patients with
hematologic malignancies receiving chemotherapy or bone mar-
row transplant. As modification of therapy from voriconazole to
fluconazole is difficult in such patient populations, the availability
of voriconazole susceptibility results is relevant for these patients.
No errors were noted in direct susceptibility testing of C.
glabrata,C. albicans, andC. tropicalis. Verymajor errors have been
reported previously in direct testing ofC. glabrata andC. tropicalis
but were not found in our study (14). On the other hand, previous
TABLE 4 Distribution of major and minor errors among the Candida
species isolates tested by disk diffusion and Etest directly from blood
culture bottles compared to the results following the standard methoda
Organism
No. (%) of isolates withh:
No
errors
Minor
errors
Major
errors Total
Disk diffusionb
C. albicans 28 1 (3.4) 0 29
C. tropicalis 25 2 (7.4) 0 27
C. parapsilosis 25 2 (7.1) 1 (3.6) 28
C. glabrata 8 0 0 8
Non-albicans Candida 4 0 0 4
C. lusitaniae 4 0 0 4
C. pelliculosa 2 0 0 2
C. albicans C. kruseid 2 0 0 2
Total for disk diffusion 98 (94.2) 5e (4.8) 1f (1.0) 104
Etestc
C. albicans 7 0 0 7
C. tropicalis 5 0 0 5
C. parapsilosis 9 0 0 9
C. glabrata 2 2 (50) 0 4
Non-albicans Candida 1 0 0 1
C. pelliculosa 2 0 0 2
C. albicans C. kruseid 0 2 (100) 0 2
Total for Etest 26 (86.7) 4g (13.3) 0 30
a The antifungals tested by Etest were fluconazole, voriconazole, amphotericin B, and
caspofungin. Caspofungin was not tested by the disk diffusion method.
b One hundred four strains were tested by disk diffusion. The Pearson chi-square value
was 4.652, and the P value was 0.99 (errors were not significantly associated with
species).
c Twenty strains were tested against all agents using the Etest, and 10 additional isolates
against at least one agent. The Pearson chi-square value was 63.44, and the P value was
0.001 (errors were significantly associated with the species C. glabrata and the mixed
species C. krusei and C. albicans).
d Direct susceptibilities were compared with standard susceptibilities of the most
resistant strain of the two isolates (C. krusei in both cases).
e There were five minor errors in determining azole susceptibilities by disk diffusion, as
follows: for voriconazole, 2 C. tropicalis isolates were reported as S-DD when they were
S and one C. parapsilosis isolate was reported as S when it was S-DD, and for
fluconazole, 1 C. albicans isolate was reported as S when it was S-DD and a C.
parapsilosis isolate as R when it was S-DD.
f There was 1 major error for fluconazole by disk diffusion (one C. parapsilosis isolate
was labeled R when it was S).
g All four cases of errors by Etest showed a minor discrepancy in caspofungin
susceptibility results (2 C. glabrata isolates were reported as S when they were I and vice
versa, and the 2 mixed cultures were reported as R and I while being I and S,
respectively). Thus, there is perfect correlation by Etest if caspofungin is not tested
directly.
h Minor errors included the reporting of S as S-DD or I or vice versa, and the major
error was the reporting of S as R.
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studies have not reported such testing errors in C. parapsilosis as
were noted in our study (14).
Antifungal susceptibility testing is not yet widely used for di-
recting treatment of invasive candidiasis, despite the fact that an-
tifungal resistance has emerged globally (28). A rapid, easy
methodof drug susceptibility testing can be expected to encourage
laboratories with limited financial and technical resources to start
monitoring antifungal susceptibilities with meaningful clinical
implications, choosing at least those agents which are most com-
monly used in their center.
Limitations. There were only four fluconazole-resistant iso-
lates and no amphotericin B- or caspofungin-resistant isolates in
our collection.Due to the small sample size and rarity of resistance
among Candida species in our study, we cannot say how the tech-
nique will perform in a setting withmore resistant isolates. There-
fore, we suggest that any unexpected results in terms of resistance
must be confirmed using standard methodology until more data
are available. Etest could not be performed for all isolates due to
financial limitations. Another limitation of this study was that
neither clinical outcomes nor tailoring of empirical antifungal
therapy in accordance with the direct drug susceptibility testing
results was recorded, as the studywas designed as an in vitro study.
Conclusion.The use of Etest for direct susceptibility testing for
Candida species has already been reported as a rapid antifungal
susceptibility testing tool that could provide results in 24 to 48 h.
The results of our study demonstrate that, as an alternative to
Etest, antifungal disks could also be used for direct susceptibility
testing for azoles. This approachwill be very useful in settings with
limited resources and expertise to allow early reporting of suscep-
tibilities that will result in prompt administration of appropriate
antifungal agents. However, the use of this technique for ampho-
tericin B testing cannot be recommended.
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